Sibel ALTUNIŞIK TOPLU, Yasemin ERSOY, Esra SAĞLAM KANDEMİR

Follow-up and treatment of primary HIV infection in Pregnancy

The pregnant population infected with "human immunodeficiency virus" (HIV), an important member of the retrovirus family, are encountered with increasing frequency in our clinical experience today. Early and effective suppression of HIV viremia will reduce the risk of mother-to-child transmission of HIV. In the light of the case we aimed to review the antiretroviral treatment (ART) options that can be used in HIV-positive pregnant women and to share an our clinical experience.

PDF

___

1. Global HIV Programme [Internet]. Available from: https://www.who.int/ teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/ hiv-data-and-statistics access date 18.08.2021
2. Estimated percentage of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission [Internet]. Available from: https://www.who.int/data/gho/data/indicators/indicatordetails/GHO/estimated-percentage-of-pregnant-women-living-with-hivwho-received-antiretrovirals-for-preventing-mother-to-child-transmission access date 21.08.2021
3. Bailey H, Zash R, Rasi V, Thorne C. HIV treatment in pregnancy. Lancet HIV. 2018;5:457–67.
4. Rothman RE, Merchant RC. Commentary. Ann Emerg Med. 2007;49:577– 9.
5. HIV-AIDS Diagnosis-Treatment Guide [Internet]. Available from: https:// hsgm.saglik.gov.tr/tr/bulasici-hastaliklar/hiv-aids/hiv-aids-liste/hiv-aidstani-tedavi-rehberi.html access date 18.08.2021
6. De Cock KM, Jaffe HW, Curran JW. The evolving epidemiology of HIV/ AIDS. Aids. 2012;26:1205–13.
7. Fenton KA. Changing epidemiology of HIV/AIDS in the United States: Implications for enhancing and promoting HIV testing strategies. Clin Infect Dis. 2007;45(Suppl 4):213-20.
8. World Health Organization. GLOBAL HIV/AIDS RESPONSE. Epidemic update and health sector progress towards Universal Access. Response. 2011;1–224.
9. Hurst SA, Appelgren KE, Kourtis AP. Prevention of mother-to-child transmission of HIV Type 1: The role of neonatal and infant prophylaxis. Expert Rev Anti Infect Ther. 2015;13:169–81.
10. Gilleece Y, Lyall H, Rubinstein L, Welch S. BHIVA guidelines on the management of pregnancy for women living with HIV. BHIVA Guidel. 2018;1–126.
11. Babb BA, Pruett MK. European AIDS Clinical society (EACS) Guidelines: Version 10.1 - October 2020. Fam Court Rev. 2020;58:867–9.
12. Brief P, Treatment HIV. Update of fırst- and second-lıne antıretrovıral regımens. Available from: https://apps.who.int/iris/bitstream/ handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf access date 2019
13. Dugdale CM, Ciaranello AL, Bekker LG, et al. Risks and benefits of dolutegravir- And efavirenz-based strategies for South African women with HIV of child-bearing potential. Ann Intern Med. 2019;170:614–25.
14. Phillips AN, Venter F, Havlir D, et al. Risks and benefits of dolutegravirbased antiretroviral drug regimens in sub-Saharan Africa: a modeling study. Lancet HIV. 2019;6:116–27.
15. Zash R, Holmes L, Diseko M, et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019;381:827-40.
16. Atta CAM, Fiest KM, Frolkis AD, et al. Global birth prevalence of spina bifida by folic acid fortification status: A systematic review and metaanalysis. Am J Public Health. 2016;106:24–34.
17. European AIDS Clinical Society Guidlines. Available from https://www. eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021 access date 10.2021